Risk factors for osteoporosis in chronic schizophrenia on long-term treatment with antipsychotics: a cross-sectional study
- PMID: 37344770
- PMCID: PMC10286449
- DOI: 10.1186/s12888-023-04951-1
Risk factors for osteoporosis in chronic schizophrenia on long-term treatment with antipsychotics: a cross-sectional study
Abstract
Background: Little is known about the laboratory variable risks with bone mineral density (BMD) in patients with schizophrenia. This study was designed to fully investigate the related risk factors for decreased BMD in schizophrenia, as well as evaluate the gender difference of BMD.
Method: The BMD of the forearm of 211 patients (males/females = 140/71) who met the diagnostic criteria for DSM-5 schizophrenia was measured by dual-energy X-ray absorptiometry. Basic demographic information, clinical assessments, and laboratory variables (regarding nutrition, hormones, metabolism, and inflammatory markers) were comprehensively collected.
Results: Among 211 subjects, seventy-four (35%) patients had low BMD. Males had a significantly lower BMD T-score than females (P = 0.002). Multiple regression analyses showed that the independent risks with low BMD were lower folate, glycosylated hemoglobin levels, higher age, serum ferritin, and follicle-stimulating hormone (FSH) levels. In female patients, the BMD was mainly associated with age and serum hormones (FSH and testosterone), while the BMD of male patients was primarily related to age, microelements (serum ferritin and 25-OH-VD), and parathyroid hormone.
Conclusion: Our study found several meaningful correlations between osteoporosis and schizophrenia, especially regarding laboratory measures, which may provide new clues to identifying or preventing osteoporosis in clinical patients.
Keywords: Bone mineral density; Gender; Osteoporosis; Risk factor; Schizophrenia.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.J Clin Psychiatry. 2008 Mar;69(3):385-91. doi: 10.4088/jcp.v69n0307. J Clin Psychiatry. 2008. PMID: 18278991
-
The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia.Arch Osteoporos. 2020 Jun 29;15(1):98. doi: 10.1007/s11657-020-00771-y. Arch Osteoporos. 2020. PMID: 32601884
-
Follicle-stimulating hormone and estradiol are associated with bone mineral density and risk of fractures in men with type 2 diabetes mellitus.J Diabetes. 2020 Jun;12(6):426-437. doi: 10.1111/1753-0407.13011. Epub 2019 Dec 18. J Diabetes. 2020. PMID: 31778286
-
Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Expert Opin Drug Saf. 2016 Jun;15(6):809-23. doi: 10.1517/14740338.2016.1167873. Epub 2016 Apr 6. Expert Opin Drug Saf. 2016. PMID: 26986209 Review.
-
Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMA.Medicine (Baltimore). 2015 Nov;94(47):e1967. doi: 10.1097/MD.0000000000001967. Medicine (Baltimore). 2015. PMID: 26632691 Free PMC article. Review.
Cited by
-
The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review.Diagnostics (Basel). 2024 Dec 5;14(23):2745. doi: 10.3390/diagnostics14232745. Diagnostics (Basel). 2024. PMID: 39682653 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous